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The optimal management of patients with non–small cell lung cancer with
ipsilateral mediastinal lymph node metastases (N2) remains controversial.
Patients with N2 disease represent a heterogeneous group that includes
atients with microscopic disease in a single lymph node and patients with bulky
etastatic adenopathy at multiple ipsilateral lymph node stations. Although many
eports have described the feasibility of neoadjuvant therapy followed by resection
n these patients, residual N2 disease at the time of resection is associated with
imited survival.1,2 In addition, pneumonectomy performed after neoadjuvant ther-
py has been associated with significant perioperative morbidity and mortality.3,4
In this issue of the Journal, Dr Cerfolio and his colleagues5 describe their
xperience with restaging the mediastinum after induction chemoradiation therapy
sing integrated positron emission tomography/computed tomography (PET/CT)
maging in 93 patients with pathologically proven N2 disease. Restaging with this
maging modality missed residual N2 disease in 13 of 65 (20%) patients with
negative” restaging evaluations and falsely suggested N2 disease in 7 of 28 (25%)
atients with “positive” restaging evaluations. Further analysis demonstrated that a
ecrease in the standardized uptake value (SUV) of the primary tumor of more than
5% or a decrease in the SUV of the N2 node initially involved with metastatic
isease of more than 50% was predictive of a significant response to the induction
herapy.
Although this study highlights some of the limitations of integrated PET/CT
estaging of the mediastinum after induction chemoradiation therapy, these results
o not suggest that it is not a useful restaging modality. First of all, integrated
ET/CT is significantly better than CT imaging alone for identifying patients who
re complete pathologic responders and those who had no evidence of residual
isease in their hilar or mediastinal lymph nodes. In an effort to limit the number of
nnecessary thoracotomies in patients with persistent N2 disease (false-negative
tudies), the authors suggest that rebiopsy of all nodal stations that originally
emonstrated metastatic disease before induction therapy could be performed by
sing minimally invasive techniques such as endoscopic ultrasonography with
ne-needle aspirate or video-assisted thoracic surgery. Similarly, biopsy of positive
odes on repeat PET/CT staging should help to identify those patients with persis-
ent metastatic disease and those with postinduction therapy inflammation.
The ultimate goal in the management of patients with non–small cell lung cancer
ho have N2 disease is to differentiate those patients who most likely will benefit
rom resection after induction therapy from those who are better served with
efinitive chemoradiation therapy. Favorable prognostic variables include radio-
raphically occult disease, metastases to a single nodal station (especially station V
odes in patients with left upper lobe tumors), and downstaging from N2 to N0-N1
isease.6-9 In these cases, it is reasonable to recommend aggressive trimodality
herapy in otherwise healthy patients. For patients with multistation nodal disease,
urgical resection after induction therapy should be reserved for those patients
hose primary tumor and residual nodal metastases can be resected completely
ithout pneumonectomy. Final results from the prospective randomized trial com-
aring definitive chemoradiation therapy to induction chemoradiation followed by
urgery in patients with N2 disease (Intergroup Trial 0139) should help to answer
mportant questions associated with this challenging clinical problem.
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